Darzalex Approved for Newly Diagnosed Stem Cell Transplant Ineligible Multiple Myeloma Patients

(July 1, 2019)

Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone has been approved by the US Food and Drug Administration  for treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem... Continue Reading

FDA Approves Polatuzumab Vedotin-Piiq for Diffuse Large B-Cell Lymphoma

(June 25, 2019)

​The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma... Continue Reading

FDA Approves Keytruda for Small Cell Lung Cancer

(June 18, 2019)

The  Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of... Continue Reading

FDA Approves Keytruda for First-line Treatment of Head and Neck Squamous Cell Carcinoma

(June 13, 2019)

FDA approves Keytruda for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Keytruda was approved for use in combination with platinum and fluorouracil (FU) for all patients and... Continue Reading

FDA Approves Chemoimmunotherapy Regimen for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

(June 11, 2019)

The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy Treanda (bendamustine) and Rituxan (rituximab) product (a combination known as “BR”), to treat adult... Continue Reading

Three-drug Combination Helps Curb Growth of Deadly Skin Cancer

(June 10, 2019)

A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma. The approach shows promise for extending the lives of people with a type of melanoma... Continue Reading

Immunotherapy comparable to chemo for some advanced stomach cancers

(June 4, 2019)

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The... Continue Reading

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

(June 3, 2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor... Continue Reading

FDA approves lenalidomide for follicular and marginal zone lymphoma

(May 30, 2019)

On May 28, 2019, the Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). The MAGNIFY... Continue Reading

Piqray® approved for the treatment of postmenopausal women with breast cancer

(May 29, 2019)

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2... Continue Reading

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

(May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

(May 7, 2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading

« Previous PageNext Page »